New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
09:29 EDTRAREUltragenyx announces license agreement with UniQuest, new U.S. patent
Ultragenyx Pharmaceutical announced a license agreement with UniQuest Pty Limited for intellectual property related to the treatment of refractory epilepsy and other seizure-related and neurologic disorders with triheptanoin. The intellectual property originated from research on epilepsy and other neurologic models conducted at The University of Queensland. Separately, a United States patent has been issued with claims directed to compositions of triheptanoin above a certain level of purity. The patent term expires in October 2025. A second U.S. patent with claims directed to compositions of triheptanoin in a dosage unit was issued in August 2013 and expires in June 2020. These patent terms do not include any potential for patent term extension of up to five additional years. Similar claims are either granted or being pursued by Ultragenyx in other territories outside the U.S.
News For RARE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
10:24 EDTRAREUltragenyx management to meet with Jefferies
Subscribe for More Information
November 12, 2014
07:53 EDTRARELeerink to hold a tour
Subscribe for More Information
November 10, 2014
15:53 EDTRARECredit Suisse to hold a conference
Healthcare Conference is being held in Scottsdale, Arizona on November 10-13 with webcasted company presentations to begin on November 11 at 10:30 am; not all company presentations may be webcasted. Webcast Link
09:05 EDTRAREUltragenyx reports Q3 EPS (50c), consensus (46c)
Emil D. Kakkis, Ph.D., M.D., CEO and president of Ultragenyx. "We are making great progress with our pipeline and look forward to initiating later-stage development in multiple programs in 2014 and 2015."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use